ArticleOncology reviews2018
Myelodysplastic syndrome from theoretical review to clinical application view.
Article in Oncology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- Research Progress on Pyroptosis in Hematological Malignancies.Current treatment options in oncology · 2023Review
- A familialCold Spring Harbor molecular case studies · 2023Article
- Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer.Nanoscale · 2022Article
- Two Cases of Hemophagocytic Lymphohistiocytosis Associated with Disseminated Histoplasmosis Presented with Transient Pancytopenia.Case reports in medicine · 2022Article
- The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?Therapeutic advances in hematology · 2022Review
- Acquired spherocytosis in the setting of myelodysplasia.Leukemia research reports · 2022Article
- Canonical Wnt: a safeguard and threat for erythropoiesis.Blood advances · 2021Review
- Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.Annals of hematology · 2021Article
- Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.Blood advances · 2021Article
- The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia.International journal of molecular sciences · 2021Review
- Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literature.Leukemia research reports · 2021Article
- Article
- Prognostic Markers of Myelodysplastic Syndromes.Medicina (Kaunas, Lithuania) · 2020Review
- Iron Overload Mimicking Conditions Skews Bone Marrow Dendritic Cells Differentiation into MHCIIInternational journal of molecular sciences · 2020Article
- Diamond-Blackfan anemia with mutation inJournal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.